Examine Cambridge Angels’ published first-round criteria and three sourced financings, distinguishing the network, members and lead investors.
By Ludovica De Pieri
Research checked 29 October 2026.
Cambridge Angels is a business angel network, so research it differently from a single pooled fund. Read its application criteria, then examine who actually led and participated in particular financings. This Teardown uses three selected announcements involving Singular Photonics, Orthofuse and xWatts. The amounts are total company rounds, not individual member cheques. They establish traceable participation, but do not show that every member invested, that the network led each round or that a similar company will be selected.
Key takeaways
- A network name in an announcement does not identify every individual investor.
- Advertised funding requirements, total rounds and member allocations are different figures.
- Use the public application criteria and source-backed questions before preparing an approach.
For a Teardown, we look for first-cheque criteria, a public route, recent activity and three traceable financing announcements. These are research checks, not investment recommendations.
Cambridge Angels' entrepreneur page, checked on 29 October 2026, says it usually considers a first equity round, gives a typical funding requirement of £150,000–£1.5 million and describes UK registration and operations criteria. It also publishes an open application route. Read the full current criteria; those selected points are not a complete eligibility test.
The three announcements below provide activity evidence. They do not prove first investment into each particular company. A network can appear alongside other investors and in different round structures.
The angels guide explains why an individual angel, network and syndicate should not be treated as interchangeable.
When an announcement names a network, record exactly that. Don't expand it into a claim that every member backed the company or that the network itself supplied the full capital.
Imagine a hypothetical founder approaching a network after meeting one member at an event. The member's interest may be useful, but it doesn't establish a decision by everyone else. The founder needs to ask about the application, screening and investment process.
The same distinction matters when reading a portfolio. One investment could involve particular people with relevant expertise, while another involves a different group. Unless a source identifies those people and their roles, leave the field unknown.
For your own research, use separate columns for network, named lead and disclosed participants. This prevents a familiar logo from concealing the parts of the financing you still need to understand.
These are sourced examples involving the network. Original currencies and the stages stated by the sources are preserved.
| Company | Announced amount and stage | Lead named by source | Cambridge Angels role |
|---|---|---|---|
| Singular Photonics | $2.15m; stage not stated | ACF Investors | Participant |
| Orthofuse | £2.2m seed | Group of angel investors | Participant |
| xWatts | £1.6m seed | Cambridge Enterprise Ventures | Participant |
None of the sources used here discloses the allocation of each Cambridge Angels member. Do not divide a total by an assumed number of investors to estimate it. A figure that looks precise would still be invented.
Singular Photonics' 19 August 2026 announcement describes $2.15 million funding led by ACF Investors, with Cambridge Angels among the participants. The company develops image sensors. The source does not state a stage label, so the table leaves it unstated.
A hypothetical founder building another sensing technology could use this as a lead for research. The next questions would concern the technical problem, customer and development work, rather than assuming any company in photonics fits.
The financing role also matters. Cambridge Angels appearing as a participant is different from leading the round. If the founder needs a lead investor, they should not treat this announcement alone as evidence that the network will take that role.
We do not use the company's sales or product-performance statements to recommend its technology or extrapolate outcomes for another business.
Orthopaedic Research UK's announcement describes £2.2 million seed funding led by a group of angels, with Cambridge Angels among the participants. ORUK identifies itself as an investor, making this a first-party co-investor account. The announcement does not display a publication date; research was checked on 29 October 2026.
The company is developing implant systems. This article makes no claim about clinical safety, approval or patient outcomes. Those subjects would require a different evidence review.
For a hypothetical founder developing a medical device, the announcement can prompt a question about whether relevant technical and regulatory expertise exists among the investors. It cannot answer that question for a specific member or establish that the founder meets current application criteria.
Keep the business description and financing facts separate from medical claims. A fundraising announcement is not a clinical study.
Parkwalk's 10 February 2026 announcement describes £1.6 million seed funding for xWatts, led by Cambridge Enterprise Ventures, with Cambridge Angels, Parkwalk and R42 participating. Parkwalk is a named participant in that round, so the source is a co-investor's account.
The business works on energy-management software. For a hypothetical founder serving building operators, that could provide a customer or workflow connection to investigate. It does not establish the same product, economics or investment case.
Do not substitute a different historical financing into this row because it appears in a university case study or a directory. Record the amount, stage and lead attached to this particular announcement.
We omit the announcement's performance percentages and customer outcomes here. They are unnecessary to the research question and have not been independently tested by this Teardown.
Some total rounds in the sample exceed the entrepreneur page's stated typical funding requirement. That does not establish that an individual member's investment exceeded a limit or that the network broke a rule.
A hypothetical £2 million round might combine several angels and institutions. A network participating in that round may represent only part of the total. Unless the source supplies the allocation, the correct answer remains unknown.
This is why a research sheet needs separate fields for application criteria, total company round and individual cheque. Treating them as one number creates a contradiction that the source itself may not contain.
If your proposed round lies outside a published range, check the current wording and ask an appropriate question through the invited route. Don't assume either rejection or an exception based on these examples.
Use a short note that states your company, relevant evidence, connection and uncertainty. It should help you decide whether to prepare an application.
Here is an invented example: “UK company developing sensor software for industrial inspections. We have a prototype and need to test it with buyers. Singular Photonics suggests relevant technical interests may exist, but our product and market differ. Need to check the network's current criteria and whether the proposed work fits.”
That is a research hypothesis, not an introduction or an indication of interest. If the company fails a published condition, mark it plainly rather than hiding it behind an adjacent investment.
The investor qualification workflow helps distinguish a reason to investigate from a reason to approach immediately.
Read the full entrepreneur page and follow its application instructions. A network's open-door policy gives you a place to submit, not a guarantee of member investment.
Keep the company's status, funding requirement and evidence consistent across the application and deck. If an adviser is checking tax-scheme eligibility, describe that process accurately and avoid promising relief to members.
For broader context, use the funding stage map. Labels can help navigation, but actual criteria and the work funded still matter.
Persephone, the investor-matching tool for UK and EU founders, helps organise source-backed investor research and draft relevant first emails. A network still needs to assess the company's case through its own process.
Newsletter
Your weekly, one-minute read on the latest news and updates across the ecosystem.
See which VCs match your startup — instant scan, no credit card required.
Try the free scan